Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-7863465-B2

Patent

Publication Date

2011-01-04

Expiration Date


Abstract

The present invention relates to novel enfumafungin derivatives of formula I and pharmaceutically acceptable salts thereof, their synthesis, and their use as inhibitors of (1,3)-β-D-glucan synthase. The present compounds and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the present compounds and pharmaceutically acceptable salts thereof, are useful for treating or preventing antifungal infections and associated diseases and conditions.

Core Innovation

The invention provides enfumafungin-derived triterpene compounds of Formula I and Formula I-a, chrysene-7-carboxylic acid derivatives, and pharmaceutically acceptable salts thereof. The structural genus encompasses defined alternatives for variable X and substituents R1 through R18, including aminoalkoxy, alkylamino, guanidino, aminated thiazole, triazolylamino, cyclic amine, and polyhydroxy side chains. These compounds inhibit fungal (1,3)-beta-D-glucan synthase and treat or prevent mycotic infections.

The disclosed compounds demonstrate antifungal activity against fungal pathogens and yeasts, including Candida, Aspergillus, and dermatophytes. Structural characterization encompasses 6-oxo core variants and salt forms, including acetate, tosylate, trifluoroacetate, and fumarate salts supported by nuclear magnetic resonance spectroscopy and mass spectrometry data. Disclosed evaluations include in vitro testing and an in vivo disseminated Candida infection mouse model.

Claims Coverage

The claims identify one independent claim containing one inventive feature directed to the Formula I compound genus and pharmaceutically acceptable salts thereof.

Formula I chrysene-7-carboxylic acid compounds and pharmaceutically acceptable salts

Claim 1 covers a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein variable X and specified substituents are selected from defined alternatives, encompassing functional groups, amino-containing side chains, and optional ring formation between substituents.

The independent claim covers the Formula I compound genus and its pharmaceutically acceptable salts, while dependent claims further specify structural variants, specific compounds, pharmaceutical compositions, and methods of treating fungal infections.

Stated Advantages

The enfumafungin-derived triterpene compounds inhibit fungal (1,3)-beta-D-glucan synthase.

The disclosed compounds exhibit antifungal activity against yeasts and fungi.

Documented Applications

Pharmaceutical compositions comprising a claim 1 compound and a carrier, adjuvant, or vehicle.

Treatment or prevention of mycotic infections in a mammal by administering an effective amount of a claim 1 compound, including infections caused by Aspergillus, Candida, and Cryptococcus species.

Treatment of fungal infections caused by Mucor, Actinomyces, Histoplasma, dermatophytes, Malassezia, Fusarium, Pneumocystis carinii, Saccharomyces, and Trichophyton species, including use in combination with established antifungal agents.

Use of the compounds to inhibit fungal (1,3)-beta-D-glucan synthase.

Evaluation of antifungal activity against Candida, Aspergillus, and dermatophytes, alongside an in vivo disseminated Candida infection mouse model.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.